title: Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report.
abstract: Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS.
authors.affiliation: Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España. Electronic address: pablocasasreza@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Casas Reza
authors.affiliation: Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España.
authors.forename: M
authors.initials: M
authors.lastname: Gestal Vázquez
authors.affiliation: Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España.
authors.forename: Á
authors.initials: Á
authors.lastname: Outeiro Rosato
authors.affiliation: Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España.
authors.forename: S
authors.initials: S
authors.lastname: López Álvarez
authors.affiliation: Servicio de Anestesiología, Reanimación y Terapéutica del Dolor, Hospital Abente y Lago, Complexo Hospitalario Universitario A Coruña, A Coruña, España.
authors.forename: P
authors.initials: P
authors.lastname: Diéguez García
mesh_terms: D000732:Androstanols / Q000008:administration & dosage*; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000009:adverse effects; D003024:Clozapine / Q000009:adverse effects; D004565:Electroconvulsive Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology / Q000628:therapy*; D061886:Neuromuscular Monitoring; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage*; D015742:Propofol / Q000008:administration & dosage / Q000494:pharmacology; D000077123:Rocuronium; D012563:Schizophrenia, Paranoid / Q000188:drug therapy / Q000628:therapy*; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000008:administration & dosage*
chemical_list: D000732:Androstanols; D018686:Anesthetics, Intravenous; D014150:Antipsychotic Agents; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D003024:Clozapine; D000077123:Rocuronium; D015742:Propofol
keywords: Electroconvulsive therapy; Esquizofrenia paranoide; Neuroleptic malignant syndrome; Neuroleptics; Neurolépticos; Paranoid schizophrenia; Rocuronio; Rocuronium; Succinilcolina; Succinylcholine; Síndrome neuroléptico maligno; Terapia electroconvulsiva